The Role of Angiotensin-Converting Enzyme (ACE) Inhibitors in Kidney Disease

Clinical Benefits of ACE Inhibitors on CKD

Despite several clinical trials demonstrating that ACE inhibitors actually favor improved renal outcomes for patients with CKD, the most significant benefit is the reduction in proteinuria, which is associated with a slowing of the progression of renal disease. Proteinuria reflects the degree of renal damage, so its reduction is thereby an important measure of therapeutic success. In clinical trials, ACE inhibitors have consistently provided a capacity to reduce proteinuria levels on the protective of the long-term preservation of kidney function.

Its use in patients with advanced chronic renal insufficiency has been proven to provide excellent renal benefits. For instance, it was found out that this class of drugs, particularly ACE inhibitors like benazepril, has significantly reduced the risk of doubling serum creatinine levels, an indication of worsening renal function among patients with advanced kidney disease that is not diabetic in origin. Moreover, ACE inhibitors provided substantial contributions to reduced progression toward ESRD and disease onset with end-stage renal disease requiring dialysis or renal transplant. All such outcomes reveal the importance of early initiation with ACE inhibitors among patients diagnosed with advanced CKD and may delay more severe renal outcomes.

As discussed, ACE inhibitors are very effective in retarding the progression of kidney disease in diabetic patients, who are known to be at a high risk of developing nephropathy. Diabetic nephropathy is one of the most common causes of ESRD, and the use of ACE inhibitors in these patients has been associated with associated favorable outcomes. In diabetic patients, the use of ACE inhibitors retards the progression of the disease by reducing glomerular hyperfiltration and proteinuria, thus delaying the onset of end-stage renal disease requiring renal replacement therapy.

ACE Inhibitors in Hypertensive Nephropathy

Hypertension is one of the causes and effects of CKD. Management and treatment of hypertension are thus crucial in the prevention of damage to the kidneys. ACE inhibitors especially provide useful blood pressure control with the added reduction in renal damage. Glomerulosclerosis caused by prolonged hypertension further accelerates the generally reduced renal function associated with hypertensive nephropathy. These consequences are prevented by ACE inhibitors, as they reduce both systemic blood pressure and the pressure within the glomeruli, that is, the filtering units of the kidneys.

In patients with hypertensive nephropathy, ACE inhibitor therapy has been successfully used to significantly slow the rate of progression of kidney disease. The study from the patients with hypertension and advanced renal insufficiency showed that ACE inhibitors not only would lower blood pressure but also slow the decline of kidney function. This two-pronged effect is particularly useful in hypertensive patients with CKD, where both systemic and renal-specific forces push forward the progression of disease.

Ace Inhibitors in Nondiabetic CKD

While most attention to ACE inhibitors has been directed to their potential role in diabetic nephropathy, they also prove highly effective in nondiabetic CKD. In nondiabetic patients, ACE inhibitors have clearly been associated with slowing the progression of kidney disease through reduction of both proteinuria and glomerular hyperfiltration. Even in nondiabetic patients with advanced renal insufficiency, ACE inhibitors have been shown to reduce risk significantly for the progression to ESRD.

Patients with nondiabetic CKD who were given benazepril experienced a major reduction in the doubling of serum creatinine and progression to ESRD in a highly successful trial. This strongly underscores the renal-protective effect of ACE inhibitors in patients beyond those with diabetes. The specific substrates for the injury in the kidney are also pivotal, with ACE inhibitors emerging as an important arm in the treatment of CKD across a wide group of patients.

Safety and Tolerability of ACE Inhibitors

Despite the highly protective effects of ACE inhibition on both the kidneys and the cardiovascular system, the side effects should not be neglected. The most frequent adverse effects include hyperkalemia, or elevated levels of potassium in the blood, which may be dangerous if untreated. Advanced CKD patients, especially, are at significant risk of developing hyperkalemia because their kidneys are less capable of excreting potassium. Therefore, it is critically important to monitor the levels of plasma potassium when ACE inhibitors are started or administered in CKD patients, especially in those with more advanced disease.

Another side effect that may be induced by ACE inhibitors is a falling rate of kidney function some time after initiation of therapy. Most of the patients will have a transient decline, known as an acute kidney injury, that resolves as their blood pressure stabilizes. In some patients, however, the AKI will be severe enough to require discontinuation of the drug. The benefits in terms of prevention of progression of CKD outweigh the short-term risks in most patients.

Other side effects that should also be watched out for include cough, a frequent side effect associated with the administration of ACE inhibitors, since bradykinin, a substance that ACE in normal conditions degrades, accumulates. In patients in whom ACE inhibitors cannot be tolerated on the basis of cough, alternative agents such as angiotensin II receptor blockers (ARBs) may be substituted; these agents provide similar renoprotection without the side effects of bradykinin.

Conclusion

ACE inhibitors have become a main role in the treatment of CKD, providing substantial renoprotection and cardiovascular benefits for a diverse population of patients. Being so in the ability to reduce proteinuria, control blood pressure, and prevent progression of kidney disease, they are becoming a modality of CKD treatment, especially in patients with comorbid conditions like hypertension and diabetes. In this regard, ACE inhibitors would address the underlying mechanisms causing the kidney damage and provide long-term protection against ESRD and subsequent dialysis or renal transplant. As the research continues to evolve, ACE inhibitors are likely to remain core therapy in the pursuit of saving millions of patients from kidney disease and improving their quality of life.

References

1. Hou, F.F., Zhang, X., Zhang, G.H., Xie, D., Chen, P.Y., Zhang, W.R., Jiang, J.P., Liang, M., Wang, G.B., Liu, Z.R. and Geng, R.W., 2006. Efficacy and safety of benazepril for advanced chronic renal insufficiency. New England Journal of Medicine, 354(2), pp.131-140.
2. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R. and Raz, I., 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine, 345(12), pp.851-860.
3. Brenner, B.M., Cooper, M.E., De Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z. and Shahinfar, S., 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England journal of medicine, 345(12), pp.861-869.
4. Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J., Charytan, D.M., Edwards, R., Agarwal, R., Bakris, G., Bull, S. and Cannon, C.P., 2019. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England journal of medicine, 380(24), pp.2295-2306.
5. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O.E., Woerle, H.J., Broedl, U.C. and Zinman, B., 2016. Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine, 375(4), pp.323-334.